Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „ruxolitinib“
Suchtreffer
Begriffe & Kennungen
Ruxolitinib Viatris · 4.5 · Enzyme inducers
Eintrag öffnenRuxolitinib Viatris · 4.5 · In healthy subjects given ruxolitinib (50 mg single dose) following the potent CYP3A4 inducer rifampicin (600
Eintrag öffnenRuxolitinib Viatris · 4.5 · Interaction studies have only been performed in adults.
Eintrag öffnenRuxolitinib Viatris · 4.5 · Interactions resulting in dose reduction of ruxolitinib
Eintrag öffnenRuxolitinib Viatris · 4.5 · It is possible that the potential inhibition of P-gp and BCRP in the intestine can be minimised if the time be
Eintrag öffnenRuxolitinib Viatris · 4.5 · Mild or moderate CYP3A4 inhibitors (such as, but not limited to, ciprofloxacin, erythromycin, amprenavir, ataz
Eintrag öffnenRuxolitinib Viatris · 4.5 · No dose adjustment is recommended when ruxolitinib is co-administered with mild or moderate CYP3A4 inhibitors
Eintrag öffnenRuxolitinib Viatris · 4.5 · Other interactions to be considered affecting ruxolitinib
Eintrag öffnenRuxolitinib Viatris · 4.5 · Patients should be closely monitored (e.g. twice weekly) for cytopenias and dose titrated based on safety and
Eintrag öffnenRuxolitinib Viatris · 4.5 · Ruxolitinib is eliminated through metabolism catalysed by CYP3A4 and CYP2C9. Thus, medicinal products inhibiti
Eintrag öffnenRuxolitinib Viatris · 4.5 · Substances transported by P-glycoprotein or other transporters Ruxolitinib may inhibit P-glycoprotein and brea
Eintrag öffnenRuxolitinib Viatris · 4.5 · When administering ruxolitinib with strong CYP3A4 inhibitors the unit dose of ruxolitinib should be reduced by
Eintrag öffnenRuxolitinib Viatris · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenRuxolitinib Viatris · 4.8 Undesirable effects · 1
Eintrag öffnenRuxolitinib Viatris · 4.8 · 12 The three most frequent non-haematological laboratory abnormalities (any CTCAE grade) identified as adverse
Eintrag öffnenRuxolitinib Viatris · 4.8 · 13 The most frequent non-haematological adverse drug reactions in REACH3 (adult and adolescent patients) and i
Eintrag öffnenRuxolitinib Viatris · 4.8 · 14 (≥1/10 000 to <1/1 000); very rare (<1/10 000); not known (cannot be estimated from the available data).
Eintrag öffnenRuxolitinib Viatris · 4.8 · 16 Thrombocytopenia1 Very common Very common Very common Very common CTCAE grade 3 Very common Very common Com
Eintrag öffnenRuxolitinib Viatris · 4.8 · 18 REACH2. In paediatric patients with chronic GvHD, grade 3 and 4 thrombocytopenia was lower (7.7% and 11.1%)
Eintrag öffnenRuxolitinib Viatris · 4.8 · 19 In the comparative period of the phase 3 acute GvHD study (REACH2), bleeding events were reported in 25.0%
Eintrag öffnen